Enanta Pharmaceuticals | ENTA - Ebitda


Enanta Pharmaceuticals reported $-36.06M in EBITDA for its fiscal quarter ending in June of 2023.





Ebitda Change Date
AbbVie USD 6.91B 3.22B Jun/2026
Amgen USD 5.8B 1.25B Sep/2026
Anika Therapeutics USD 4.54M 3.67M Dec/2025
Arrowhead Research USD -147.68M 40.33M Jun/2026
AstraZeneca USD 7.46B 2.3B Sep/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Biogen USD 450.8M 198.9M Jun/2026
Bristol-Myers Squibb USD 3.48B 1.6B Sep/2026
Gilead Sciences USD -9.31B 12.82B Jun/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
Halozyme Therapeutics USD 328.81M 109.24M Jun/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Immunic USD -22.78M 753K Jun/2024
Incyte USD 778.57M 410.6M Jun/2026
Insmed USD -80.97M 93.7M Sep/2026
Ionis Pharmaceuticals USD -64.53M 135.49M Mar/2026
J&J USD 8.99B 721M Jun/2026
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Ligand Pharmaceuticals USD 74.27M 88.56M Jun/2026
Merck USD 1.42B 2.97B Jun/2026
Neurocrine Biosciences USD 375.3M 185.4M Sep/2026
Novartis USD 8.62B 2.14B Sep/2026
Novavax USD 19.36M 190.79M Dec/2025
Pfizer USD 6.36B 350M Sep/2026
PTC Therapeutics USD 161.9M 99.92M Jun/2026
Roche Holding CHF 13.43B 744M Jun/2026
Sarepta Therapeutics USD 30.17M 345.31M Jun/2026
Vertex Pharmaceuticals USD 1.33B 130.5M Jun/2026